Results 161 to 170 of about 47,993 (230)

Clinical and Genetic Overview of Neurofibromatosis Type 2 (NF2). [PDF]

J Korean Neurosurg Soc
Kim TK, Park YS, Nakagawa I.
europepmc   +1 more source

Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma. [PDF]

Mod Pathol, 2023
Li Y, Yang SR, Chen YB, Adusumilli PS, Bialik A, Bodd FM, Ladanyi M, Lopardo J, Offin MD, Rusch VW, Travis WD, Zauderer MG, Chang JC, Sauter JL.   +13 more
europepmc   +1 more source

Matrix Metalloproteinase‑9 (MMP-9) Activatable Gold Nanoparticles for <i>In Situ</i> Zymography and Diagnostics of Neurofibromatosis Type 2 (NF2) Tumors. [PDF]

ACS Appl Nano Mater
Kaushal S, Nguyen HTN, Fisher M, Kuo HC, Schultz ZD, Ren Y.   +5 more
europepmc   +1 more source

Meningiomas in patients with neurofibromatosis type 2 predominantly comprise 'immunogenic subtype' tumours characterised by macrophage infiltration. [PDF]

Acta Neuropathol Commun, 2023
Teranishi Y, Miyawaki S, Nakatochi M, Okano A, Ohara K, Hongo H, Ishigami D, Sakai Y, Shimada D, Takayanagi S, Ikemura M, Komura D, Katoh H, Mitsui J, Morishita S, Ushiku T, Ishikawa S, Nakatomi H, Saito N.   +18 more
europepmc   +1 more source

Investigating cochlear cellular dynamics in neurofibromatosis type 2-associated schwannomatosis: a histopathological study. [PDF]

Front Neurol
Al-Asad RK, Montigny DJ, O'Malley JT, Welling DB, Jung DH, Eckhard AH, Kempfle JS.   +6 more
europepmc   +1 more source

Context-specific targeting of focal adhesion kinase in brain tumors: lessons from glioblastoma and neurofibromatosis type 2-mutant meningioma. [PDF]

Front Oncol
Sagerer A, Eyüpoglu IY, Juratli TA, Cordes N.   +3 more
europepmc   +1 more source

Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2. [PDF]

Curr Oncol, 2023
Sarkar S, Throckmorton W, Bingham R, Msaouel P, Genovese G, Slopis J, Rao P, Sadighi Z, Herzog CE.   +8 more
europepmc   +1 more source

Short‑term efficacy assessment of brigatinib for the treatment of neurofibromatosis type 2: A retrospective study. [PDF]

Oncol Lett
Lin Z, Yu W, Jing F, Xu Z, Liu M, Jiao S.   +5 more
europepmc   +1 more source

Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2: a systematic review and meta-analysis. [PDF]

BMC Cancer
Hajikarimloo B, Tos SM, Alvani MS, Kooshki A, Mohammadzadeh I, Habibi MA.   +5 more
europepmc   +1 more source

Erratum: Subacute brainstem ischemic syndrome in juvenile neurofibromatosis type 2: An under-recognized condition. [PDF]

Clin Case Rep, 2023
Blauen A, Lenfant C, Duprez T, Nassogne MC.   +3 more
europepmc   +1 more source